Clinical Study of CIVO™ Platform

Clinical Study of CIVO™ Platform

CIVO™ is currently being evaluated in a clinical study in humans in collaboration with the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, with funding provided by the National Cancer Institute (NCI). The study evaluates the response to locally injected drugs from the R-CHOP regimen in newly diagnosed or recurrent lymphoma patients and evaluates the safety profile of CIVO™ microinjections. This observational study is intended to test the overall coordination of the CIVO™ system, from the oncologist performing the injection correctly to the surgeon’s resection of the tumor and the subsequent quantitative analysis. No results are reported back to the oncologists or the patients, and no change in the patients’ treatments will result from this initial trial.

We expect this work to set the stage for subsequent microinjections of investigational agents, thereby realizing the innovative vision of early clinical, toxicity-sparing efficacy studies.

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO™ Microdosing System

The clinical trial is currently open and recruiting patients. For additional information, please follow the links below to access the complete trial protocol listing as posted on the National Institutes of Health (NIH) clinical trials website (www.clinicaltrials.gov). General information on clinical trials, including a glossary of terms, can be found by visiting the NIH website.